INTRODUCTION {#s1}
============

Photodynamic action: a brief history of cancer treatment {#s1_1}
--------------------------------------------------------

In the western World, the term photodynamic action, a literal translation of the German word "Wirkung der photodynamischen", was coined by von Tappeiner and collaborators to differentiate photodynamic action from the sensitization that occurs in photography films \[[@R1], [@R2]\]. At the time, Von Tappeiner\'s group was investigating the effect of antimalarial drugs on certain protozoa. A PhD student, Raab, discovered that certain dyes, such as Acridine, display phototoxic effects on *Paramaecium caudatum* only when exposed to sunlight \[[@R3], [@R4]\]. This was observed by chance, with controversial results, since the effects apparently depended on the sunlight conditions of their Laboratory at the Munich University. It is relevant to point out that Marcacci had recognized the phototoxicity of quinine on oocytes \[[@R5]\], but this seems to have been unknown by Von Tappeiner\'s team at the time.

Von Tappeiner quickly recognized the clinical potential of Raab\'s data, since he was apparently familiar with the work of a French neurologist that attempted to apply eosin to treat epilepsy, causing photoxicity skin effects \[[@R6]\]. Possibly based on that study, and on their own data, Von Tappeiner, H., and Jesionek, A. treated three patients presenting skin cancer and other pathologies with Photodynamic Therapy (PDT) \[[@R7]\]. In 1905, they treated more five patients presenting skin cancer, with good results \[[@R8]\]. The use of PDT to treat *in vivo* tumors was little explored until 1972, when Diamond and co-workers demonstrated a small decrease in tumors derived from a glioma cell line implanted in rats exposed to light and treated with haematoporphyrin \[[@R9]\]. In 1975, a breakthrough study was published on eleven human bladder carcinomas xenografted to artificially immunosuppressed mice treated with PDT, that demonstrated remarkable damage to the tumors \[[@R10]\]. Since then, PDT has been used to treat several cancer types easily exposed to light sources \[[@R11]\]. Most are skin cancers or tumors easily accessed by endoscopy devices. The largest obstacle for PDT application is the light necessary to reach deep into the cancer tissues.

General photodynamic therapy aspects {#s1_2}
------------------------------------

PDT has emerged as a promising alternative or as a possible combination to conventional treatments, such as surgery, chemotherapy and radiotherapy \[[@R12]\]. It is based on the use of a systemically or locally administrated photosensitive molecule. Once "excited" by light at an appropriate wavelength, the photosensitive molecule undergoes electronic transitions to higher energy states, making it reactive to several compounds in the surrounding environment \[[@R13]--[@R18]\]. Photosensitizers, as these photosensitive molecules are known, are excited in the presence of light. In the presence of molecular oxygen, this process, leads to a series of photochemical reactions that culminate in the generation of free radicals and singlet oxygens (highly reactive chemical species derived from molecular oxygen). These photochemical reactions cause oxidative damage and target cell death \[[@R13], [@R14]\]. The existence of modern laboratory apparatuses and fiber-optic endoscopy systems allow for light application at the appropriate wavelength in several parts of the body, permitting PDT application to internal tumors \[[@R19]\]. Figure [1](#F1){ref-type="fig"} illustrates photodynamic therapy principles.

![Schematic representation of photodynamic therapy\
(**A**) A photosensitizer (PS) is systemically or topically administered. (**B**) After systemic PS distribution, it selectively accumulates in the tumor, represented by red circles. (**C**) In cooperation to laparoscopic techniques, the cancer cells are irradiated with red light. Irradiation activates the PS and triggers a photochemical reaction in the presence of molecular oxygen, culminating in the production of singlet oxygen species (1O2). (**D**) Damage to cellular macromolecules leads to tumor cell death by different processes, such as apoptotic, necrotic and autophagic mechanisms.](oncotarget-09-25342-g001){#F1}

PDT efficiency depends on a high number of physicochemical and physiological properties, such as type of photosensitizer, drug concentrations, location of the photosensitizer in the tumor, adequate dosimetry (total light dose, exposure time and form of light exposure) and oxygen availability \[[@R16], [@R17]\]. PDT success requires specific conditions aiming at the high production of singlet oxygen, since numerous studies have demonstrated that this chemical species is the primary responsible for PDT cytotoxic effects \[[@R15], [@R20], [@R21]\]. Tissue light penetration is dependent on tissue characteristics and wavelength. Wavelengths in the red or infrared range are recommended for clinical application, since they exhibit greater tissue penetration within a "therapeutic window", from 600 nm to 800 nm, which produces enough energy to support the formation of singlet oxygen species \[[@R15], [@R18]\]. To overcome this light penetration problem, Chen *et al.,* 2006 \[[@R22]\] proposed the use of synthesized nanoparticles (nanoscintillators), which can absorb X-rays and generate visible light.

Nanoscintillators {#s1_3}
-----------------

Scintillation is the capability that certain substances present to emit light, triggered by interactions with ionizing radiation. Nanoparticles, as the name suggests, range from 10 to 1000 nm, although in terms of biological significance, the range from 10 to 100 nm is the most applied \[[@R23]\]. Nanoscintillators are composed of inorganic salts, most doped with rare earth metals as depicted in Table [1](#T1){ref-type="table"}.

###### Use of X- rays with nanoscintillators in different biological models

  Year   Nanoparticle                      Size        Nanoparticle concentration   Photosensitizer                                   X-rays energy           Biological Model           References
  ------ --------------------------------- ----------- ---------------------------- ------------------------------------------------- ----------------------- -------------------------- -------------------------------------
  2008   LaF~3~:Tb^3+^                     15 nm       0.035 M                      Meso-tetra (4-carboxyphenyl) porphine (MTCP)      120 keV                 N/A                        Liu YF, *et al*. \[[@R88]\]
  2010   ZnO nanorods (NRs)                0.5 μm      N/A                          P rotoporphyrin dimethyl ester (PPDME)            N/A                     T47D cells                 Kishwar S, *et al*. \[[@R89]\]
  2011   Y~2~O~3~                          12 nm       2.5--95 μg/mL                Psoralen                                          2 Gy, 160 or 320 kVp    PC3 cells                  Scaffidi JP, *et al*. \[[@R90]\]
  2011   Gd~2~O~2~S:Tb                     20 μm       5 mg/mL                      Photofrin II                                      120 keV, 20 mAs         Human glioblastoma cells   Abliz E, *et al*. \[[@R91]\]
  2013   Tb~2~O~3~                         10 nm       1 mM                         Porphyrin                                         N/A                     N/A                        Bulin AL, *et al*. \[[@R92]\]
  2013   ZnO                               50 nm       0.3--0.6 μM                  meso-tetra (4-sulfonatophenyl) porphyrin (TSPP)   N/A                     Escherichia coli           Senthilkumar S, *et al*. \[[@R93]\]
  2014   LaF~3~:Ce^3+^                     2 μm        1 μg/mL                      Protoporphyrin IX (PPIX)                          3 Gy                    PC3 cells                  Zou X, *et al*. \[[@R94]\]
  2016   Sr~2~MgSi~2~O~7~:Eu^2+^, Dy^3+^   273 nm      10 μg/mL                     Protoporphyrin IX (PPIX)                          1-7 Gy                  PC3                        Homayoni H, *et al*. \[[@R95]\]
  2014   Cu−Cy                             50−100 nm   50 μg                        Self                                              5 Gy                    MCF-7 xenograft            L Ma, *et al*. \[[@R96]\]
  2016   ZnS:Cu, Co                        4 nm        0.05 mM                      Tetrabromorhodamine-123 (TBrRh123)                2 Gy                    PC3 cells                  L Ma, *et al*. \[[@R97]\]
  2015   SrAl~2~O~4~:Eu^2+^                80 nm       50 μg/mL                     Merocyanine 540 (MC540)                           0.5 Gy                  U87MG xenograft            Chen H, *et al*. \[[@R98]\]
  2015   LaF~3~:Tb                         3−45 nm     N/A                          Rose Bengal (RB)                                  2−10 keV                N/A                        Tang Y, *et al*. \[[@R99]\]
  2015   LaF~3~:Tb                         3−45 nm     20 mg/mL                     Rose Bengal (RB)                                  N/A                     Tumor model                Elmenoufy AH, *et al*. \[[@R100]\]
  2016   CeF~3~                            7−11 nm     0.1--0.9 μM                  Veterporfin (VP)                                  6 Gy, 8 keV, or 6 MeV   Panc-1                     Clement S, *et al*. \[[@R101]\]
  2015   LiYF4:Ce^3+^                      34 nm       25-50 μg/mL                  ZnO                                               8 Gy                    HeLa cells                 Zhang C, *et al*. \[[@R102]\]
  2015   SiC/SiOx NWs                      20 nm       50 μg/mL                     Porphyrin                                         2 Gy, 6 MV              A549 cells                 Rossi F, *et al*. \[[@R103]\]
  2015   ZnO/SiO~3~                        98 nm       0.005--0.05 M                ZnO                                               200 kVp, 2 Gy           LNCaP and Du145 cells      Generalov R, *et al*. \[[@R104]\]
  2015   GdEuC~12~ micelle                 4.6 nm      500 μM                       Hypericin (Hyp)                                   5--40 KeV               HeLa cells                 Kascakova S, *et al*. \[[@R105]\]

N/A = Not applicable.

The great advantage of nanoscintillators is the possibility of applying low energy X-rays (300 KeV) to generate light, thus diminishing radiotherapy side effects or allowing for combined use with chemotherapy. Radiotherapy normally applied energies ranging from 6 to 20 MeV. X-rays show great penetration capacity, reaching regions inaccessible to visible light, such as the brain or deep regions in tumors (more than 5 mm).

Photodynamic therapy clinical applications {#s1_4}
------------------------------------------

PDT is a promising alternative for the treatment of infectious diseases and infected blood and derivatives, as well as for the photoinactivation of multiresistant strains or microbial biofilms \[[@R24]--[@R26]\] (see Table [2](#T2){ref-type="table"}). In comparison to the usual cancer treatment procedures (radiotherapy, chemotherapy and surgery), PDT displays a number of advantages. It is non-invasive and can be applied to virtually all types of cancer. For example, Temoporfin Foscan^®^ (a first generation photosensitizer), was applied for the treatment of lung, gastric, prostate and skin cancers \[[@R27]\]. PDT may also be used repeatedly without producing side effects, usually showing excellent healing results \[[@R28]\]. In addition, tissue preservation leads to practically no fibrosis, thereby conserving the functional anatomy and mechanical integrity of the organs undergoing the procedure, as well as selective tumor removal without secondary detrimental effect on surrounding healthy tissues \[[@R29]\]. PDT can also be used before or after aforementioned conventional treatments without compromising these therapeutic modalities. In addition, due to the inactivation of the photosensitizer in the absence of light, PTD shows low systemic toxicity. Finally, many PDT procedures can be performed in an ambulatory environment, lowering costs and making the procedure more acceptable to patients, resulting in increased patient adherence to treatment \[[@R28], [@R30], [@R31]\].

###### Use of MB in different PDT

  Year   Patient number   MB concentration                        Administration                                    Indication                                                                                    Light Energy       Wavelength light source   References
  ------ ---------------- --------------------------------------- ------------------------------------------------- --------------------------------------------------------------------------------------------- ------------------ ------------------------- --------------------------------------------
  2005   60               2% dissolved in acetone                 Injection                                         Onychomycosis                                                                                 18 J/cm^2^         600 to 750 nm             Tardivo JP, *et al*. \[[@R46]\]
  2005   10               2% aqueous solution                     Intratumor injection                              Metastatic melanoma, Basal cell carcinoma, Squamous cell, Breast cancer, Kaposi\'s sarcoma.   18 to 36 J/cm^2^   600 to 750 nm             Tardivo JP, *et al*. \[[@R46], [@R85]\]
  2015   20               2% aqueous solution and 0,2% hydrogel   Intralesional injection and topically             Nodular or ulcerative basal cell carcinoma                                                    48 J/cm^2^         N.I                       Samy NA, *et al*. \[[@R106]\]
  1997   3                10%                                     Topically                                         chronic plaque-stage psoriasis                                                                5 J/cm^2^          600 to 700 nm             Schick E, *et al*. \[[@R107]\]
  2006   26               5% aqueous solution                     Gargle                                            Oral Lichen Planus                                                                            120 J/cm^2^        632 nm                    Aghahosseini F, *et al*. \[[@R108]\]
  2009   16               0,1% hydrogel                           Topically                                         Resistant psoriatic plaque                                                                    565 mW             670 nm                    Salah M, *et al*. \[[@R109]\]
  2014   80               2% aqueous solution                     Oral administration                               onychomycosis                                                                                 18 J/cm^2^         630 nm                    Figueiredo Souza L W, *et al*. \[[@R110]\]
  2009   13               0,1% hydrogel                           Topically                                         Acne vulgaris                                                                                                                              Fadel M, *et al*. \[[@R111]\]
  2014   18               1% aqueous solution                     Irrigation using syringes and catheters           Neuropathy, ulceration and infection in diabetic patin                                        30 J/cm^2^         400 to 725 nm             Tardivo JP, *et al*. \[[@R112]\]
  1995   3                1% aqueous solution                     Intratumor injection                              Inoperable oesophageal tumours                                                                7 J/cm^2^          662 nm                    Orth K, *et al*. \[[@R52]\]
  2012   12               0.01%                                   applied at the bottom of the periodontal pocket   Periodontitis in HIV patients                                                                 0,03 W             660 nm                    Noro Filho, *et al*. \[[@R113]\]

N.I = not informed.

Photosensitizers {#s1_5}
----------------

Photosensitizing (PS) agents are essential PDT components. They are responsible for transferring the energy required for the occurrence of photochemical reactions that result in selective cell or tissue destruction \[[@R32]\]. A wide range of natural and synthetic compounds are capable of absorbing radiation in the UV-visible spectrum and generating singlet oxygen species, such as plant-derived products and synthetic macrocyclic complexes \[[@R14]\]. To function as a photosensitizer, a molecule must exhibit the following properties: (1) a high absorption coefficient in the spectral region of the excitation light source; (2) an appropriate triplet energy state (E~T~ ≥ 95 kJ.mol^-1^), in order to transfer to molecular oxygen in the ground state; (3) a high quantum triplet yield (φ~T~ ≥ 0.4), long triplet half-life state (τ~T~ ≥ 1 μs) and (4) a high photostability state \[[@R33]\].

Over 1450 molecules with potential PDT applications have been catalogued \[[@R34]\]. However, only some may be applied for this purpose, since the costs for their introduction into the clinical practice related to clinical tests are quite high. Thus, only sensitizers with "exceptional" properties justify the financial expenditure \[[@R34]\]. In addition to suitable chemical and physical properties, other characteristics are recommended for a drug to be considered optimal for PDT, including high chemical purity and rigorous and simple chemical synthesis; preferential accumulation at the site of interest; lack of toxicity in the dark; strong phototoxicity; rapid clearance from normal tissues; amphiphilicity; easy administration by various routes; low manufacturing cost and easy storage and marketing \[[@R15], [@R35], [@R36]\].

Photosensitizers can be classified according to their structure or origin. A traditional classification separates these compounds into three generations. Porphyrins and other substances developed in the 70\'s or early 80\'s are named first-generation photosensitizers, while porphyrin derivatives or synthetic compounds produced in the late 80\'s are termed second-generation photosensitizers. Third generation photosensitizers refer to changes carried out in their structures leading to selective tumor accumulation, like organic conjugates (liposomes or conjugated to antibodies) \[[@R32], [@R35]\]. Furthermore, existing photosensitizers can be classified into three large families: (1) porphyrin-based photosensitizers (eg, Photofrin, ALA/PpIX, BPD-MA); (2) chlorophyll-based photosensitizers (eg chlorins, purplish, bacteriochlorins); and (3) dyes (phthalocyanines, naphthalocyanines, methylene blue) \[[@R35]\].

Clinically- or experimentally-applied photosensitizers include many metallocomplexes which generally exhibit maximum absorption bands in the visible red spectrum and a molar extinction coefficient ranging from 10^3^ to 10^5^ M^−1^.cm^−1^ \[[@R37]\]. Most are based on a tetrapyrrole aromatic nucleus, similar to the protoporphyrin found in hemoglobin. These rings exhibit a relatively broad absorption band in the 400 nm region, known as the Soret band, and a group of minor bands directed to red wavelengths, known as the Q-band \[[@R38]\]. Hematoporphyrin derivatives (HpD) and porfirmer sodium (Photofrin) obtained from subsequent purifications are prototype drugs and were the first to be applied in the clinical practice. Despite their success as tools for the treatment of cancer and other conditions, these compounds display some disadvantages, such as lack of chemical homogeneity, slow skin clearance, resulting in long-term photosensitivity, and poor absorption in the clinical wavelength (ε = 10^3^ M^−1^. cm^−1^ at 640 nm), where light shows adequate tissue penetration \[[@R14], [@R36]\]. This has motivated the search for new photosensitizers that would exceed these limitations and present appropriate photophysical and photochemical properties.

Methylene blue (MB) characteristics {#s1_6}
-----------------------------------

Among second-generation photosensitizers, phenothiazine dyes are noted for displaying desirable photophysical and photochemical characteristics for PDT applications, such as high production of singlet oxygen species and strong absorption in therapeutic range (600--750 nm) \[[@R39]\]. Chemically, these compounds are formed by two main portions, namely chromospheres, which are aromatic ring systems with delocalized p-electrons, and peripheral modifications, such as side chains and auxochromes. This heterocyclic ring system has long been established and its chemical synthesis is well understood, allowing for easy analogue preparation \[[@R40]\]. Two main classes of phenothiazines are used in the medical practice: oxidized phenothiazines, planar and tricyclic (MB, thionine and toluidine blue), and non-oxidized molecules, such as promethazine and chlorpromazine, that are not completely aromatic or planar. Typically, phenothiazine dyes present a delocalized positive charge at neutral pH in the ring system, whereas phenothiazine neuroleptics exhibit a positive charge located at the nitrogen distal side chain. Phenothiazine compounds display great versatility concerning possible applications in medical practice, and are studied regarding their therapeutic role in the local treatment of bacterial infections, tuberculosis, trypanosomiasis, malaria, rickettsia infections, fungal infections and cancer \[[@R41]\]. Regarding cancer PDT applications, the most researched compounds are methylene blue (IUPAC name: 3,7-bis(Dimethylamino)-phenothiazin-5-ium chloride) and toluidine blue, which are structurally and physicochemically similar. Both possess a nitrogen atom capable of accepting protons in the center ring and two nitrogen atoms that contribute to charge relocation in the chromophore by stabilizing the cationic form.

MB has been widely applied as a vital dye for over a century \[[@R42], [@R43]\]. It was first synthesized in the nineteenth century (1876) by Heinrich Caro, who worked at Badische Anilin und Soda-Fabrik, a German chemical industry, from the oxidation of p-dimethylaniline \[[@R44]\]. In the late nineteenth century, scientists Robert Koch and Paul Ehrlich used MB to stain microorganisms. Based on these studies, Erlich envisioned that these could also be applied therapeutically. In fact, in 1891, he demonstrated that MB was effective in treating malaria in humans \[[@R45]\].

MB shows an intense color in aqueous solutions due to the intense absorption of the phenothiazine chromophore at 600--700 nm in the visible spectrum, with a well-defined peak at 664--666 nm \[[@R39], [@R46]\]. A less intense peak can be observed in or near the UV region, particularly from 284 to 300 nm \[[@R42]\]. Moreover, this compound can also generate radicals, even in the presence of reducing agents \[[@R46]\]. In aqueous solutions, the excitation spectrum is concentration-dependent due to dimerization and oligomerization phenomena, whose equilibrium constant is 3.8 × 10^−3^ M^−1^ \[[@R46]\]. Between 10^−5^ and 10^−3^ M, MB aggregation is limited to dimer formation. Dimerization increases with ionic strength and can increase or decrease the presence of charged interfaces, depending on the relationship between the dye and the interface \[[@R47]\]. Monomers and dimers have very distinct absorption bands, with the dimer band 60 nm shorter compared to the monomer band. Similarly to many inorganic dyes, MB does not follow the Beer-Lambert law \[[@R43]\], probably due to the reversible formation of polymers, which are maintained together by the dispersion forces originating from delocalized p electrons in the individual dye molecules \[[@R44]\]. The photodynamic mechanism for MB is quite complex. It has a high quantum yield of intersystem crossing (Φ~Δ~ \~ 0.5), which can generate high singlet oxygen species concentrations and mediate cytotoxicity to form hydroxyl radicals, which in turn can alter intracellular Ca^2+^ homeostasis \[[@R48], [@R49]\].

MB is characterized by its low toxicity and can be used in the intraoperative or endoscopic marking of various tumors, as well as in the clinical treatment for methemoglobinemia \[[@R14], [@R49]\]. Although idiosyncratic reactions may occur, MB doses are high without the occurrence of measurable toxicity. For example, concentrations routinely used for staining the oral and nasopharyngeal mucosa are in the millimole range (1% w/w or 31,2 mM) \[[@R39]\]. Additionally, MB pharmacokinetics are well established and have shown different distribution profiles, depending on the administration route \[[@R50]\].

Several studies considering MB for the treatment of neoplasms have been reported. *In vitro* studies have demonstrated that MB shows phototoxicity against several tumor cell lines, such as cervical cancer adenocarcinomas (HeLa) and bladder carcinomas \[[@R51]\]. Local MB administration has also been applied in the treatment of inoperable esophageal tumor \[[@R52]\]. However, oncology MB clinical applications have been limited due to its lack of activity when applied systemically. This weak pharmaceutical activity results in poor penetration of tumor cellular environment \[[@R53]\].

Strategies to improve MB cell entry {#s1_7}
-----------------------------------

In this scenario, it is, thus, essential to search for pathways that may facilitate MB a hydrophilic drug, uptake into target cells, leading to feasible tumor treatments. In this context, pore-forming proteins are present in the plasma membrane of many mammalian cell types, able to open under physiological or pathophysiological conditions, such as changes in cell volume, hypoxia and alterations in extracellular pH, among others. When open, they allow for the passage of molecules of up to 1,000 Da without necessarily leading to cell death. Among pore-forming proteins, pannexin-1 \[[@R54]\], connexin hemichannels \[[@R55]\], TRPV1-4 subtypes and TRPA1 \[[@R56]\], calcium homeostasis modulator 1 (CALHM1) \[[@R57]\], Maxi anion \[[@R58]\], plasma membrane VDAC \[[@R59]\] and ATP-gated subtypes P2×2 \[[@R60]--[@R62]\], P2×4 \[[@R63]--[@R65]\] and, especially, P2×7 receptors \[[@R66]--[@R68]\] are noteworthy (Figure [2](#F2){ref-type="fig"}). One possibility would be to study the involvement of the P2×7 associated-pore as an MB uptake route in the cytoplasm of neoplastic cells, and, in this regard, we have recently demonstrated that P2×7 can function as a drug delivery system in the J774 tumor cell line \[[@R69]\].

![Using the pore associated with P2×7 receptor and other pores as an entry pathway for methylene blue (319 Da) in PDT](oncotarget-09-25342-g002){#F2}

Since this receptor is related to several physiological processes, such as T-cell maturation, innate immune response activation, epithelial secretion, mineralization regulation, bone resorption and fast synaptic transmission, among others, it is not surprising that it is also associated to several pathological conditions. Indeed, P2×7 polymorphisms have been associated with susceptibility to infectious neurodegenerative diseases, depression, osteoporosis and inflammatory diseases \[[@R70]--[@R77]\].

In this context, several groups have investigated the role of P2×7 in tumor pathophysiology, mainly due to its cytotoxic potential, which can exploited as a pharmacological target. Its expression (mRNA and protein) has been demonstrated in different tumor and tumor cell lines subtype (Table [3](#T3){ref-type="table"}), but no consensus ion its function has been reached. Nevertheless, evidence clearly shows a dependence on the cellular model under study, as this receptor may be involved with growth/proliferation or death induction (apoptosis/necrosis) \[[@R78]--[@R84]\].

###### P2×7 expression and functions in neoplasms

  Year   Tumor type                     Expression level   Physiological effect of the activation                               References
  ------ ------------------------------ ------------------ -------------------------------------------------------------------- -----------------------------------------
  2005   Prostate                       Protein            No determined                                                        Slater M, *et al*. \[[@R114]\]
  2013   Breast                         mRNA/Protein       Increases intracellular Ca^2+^ concentration                         Jelassi B, *et al*. \[[@R115]\]
  2008   Thyroid                        mRNA/Protein       Not determined                                                       Solini A, *et al.* \[[@R116]\]
  2007   Pancreas                       mRNA               Not determined                                                       Kunzli BM, *et al.* \[[@R117]\]
  2005   Skin carcinoma                 mRNA               Not determined                                                       Slater M, *et al.* \[[@R114]\]
  2006   Uterine epithelial             mRNA/Protein       Not determined                                                       Li X, *et al.* \[[@R118]\]
  2006   Neuroblastoma                  mRNA/Protein       Induce cell proliferation                                            Raffaghello L, *et al.* \[[@R119]\]
  2005   Melanoma                       mRNA/Protein       YO-PRO-1 uptake                                                      White N, *et al.* \[[@R120]\]
  2002   Chronic Lymphocytic Leukemia   mRNA/Protein       Decrease the proliferation                                           Adinolfi E, *et al.* \[[@R121]\]
  2015   Hepatocellular carcinoma       mRNA/Protein       Not determined                                                       Liu H, *et al.* \[[@R122]\]
  2014   Ovarian carcinoma              mRNA/Protein       Increase of intracellular Ca^2+^ concentration, but not cell death   Vázquez-Cuevas FG, *et al.* \[[@R123]\]
  2010   Papillary thyroid carcinoma    Protein            Not determined                                                       Gu LQ, *et al.* \[[@R124]\]
  2012   Lung cancer                    mRNA/Protein       Ethidium uptake                                                      Takai E, *et al.* \[[@R125]\]
  2012   Glioma                         mRNA/Protein       Ethidium uptake                                                      Gehring MP, *et al.* \[[@R126]\]
  2013   Colorectal cancer              mRNA               Ethidium uptake                                                      Bian S, *et al.* \[[@R127]\]

MB and the P2×7 receptor {#s1_8}
------------------------

Although knowledge on tumor biology has advanced greatly in recent years, the approval of new cancer treatment drugs is still limited. In addition, traditional therapies, such as chemotherapy and radiotherapy, lack selectivity and possess numerous side effects. Accordingly, PDT emerges as a promising alternative, displaying very positive results over the years. MB stands out among photosensitizers with possible applications in clinical practice, since it displays excellent photodynamic properties and low toxicity in humans. However, its use has been limited due to its low tumor penetration \[[@R85], [@R86]\] The literature describes several strategies to increase MB uptake by tumor tissues, such as altering its chemical structure in order to increase lipophilicity, or its association with three-dimensional structures, allowing access to the cytoplasm, as cited previously. Herein, we propose another possibility, of using transient membrane pores, such as the pore induced by activation of the P2×7 receptor. Interestingly, this receptor has been described in certain types of tumors, making it an adequate target for pharmacological tumor therapy. This strategy could enhance PDT once MB is at a size able to pass through the pore (319 Da). Figure [3](#F3){ref-type="fig"} displays a scheme representing this hypothesis, in which a cell is exposed to MB along with ATP administration at concentrations sufficient enough to open the P2×7 pore for 15 to 20 minutes. After the incubation period, the cells would be exposed to light in the appropriate wavelength (600--700 nm) in order to activate MB photodynamic activity. Furthermore, following the system upgrades as displayed in Figure [3](#F3){ref-type="fig"}, radioluminescent molecules, which produce luminescence in the red spectrum excited by low-intensity X-ray, would become even more selective and exhibit fewer side effects \[[@R87]\], as previously outlined in Figure [3](#F3){ref-type="fig"}.

![Photodynamic therapy may increase selectivity when applied concurrently to photosensitizing (PS) radioluminescent molecules (RL)\
(**A**) A tumor with high P2×7 expression can be treated with the application of Methylene blue (MB), a potent Photosensitizer (PS), nanoparticles and ATP. (**B**) These compounds in solution form are administered directly into the venous circulation via syringe and, once in the blood, can migrate to any part of the body. ATP administration activates the pore associated to the P2×7 receptor, allowing for MB passage. (**C**) The RL, once excited by low intensity X-rays, emit luminescence in the red spectrum. Thus, the luminescence produced by the radioluminescent molecule leads to an excited state of the photosensitizer (PS^\*^), initiating a series of photochemical reactions in the tumor environment, resulting in the production of singlet oxygen species (1O2) from molecular oxygen (3O2), which is a highly reactive and cytotoxic chemical species.](oncotarget-09-25342-g003){#F3}

**CONFLICTS OF INTEREST**

None.
